Innovating CMC for Oligonucleotide and Peptide Therapeutics - Innovating CMC for Oligonucleotide and Peptide Therapeutics

Innovating CMC for Oligonucleotide and Peptide TherapeuticsJune 2020In this first edition of the TIDES eBook Series, we explore ways in which chemistry, manufacturing and controls (CMC) can be optimized.Contents

Introduction & Contents

Case Study: Generating a SARS-CoV-2 Epitope Library

CMC Approaches to Accelerate Peptide, Oligonucleotide and mRNA Therapeutic Development

Partnering in the Oligonucleotide and Peptide Therapeutics Industry

How AI Could Revolutionize Chemistry

Q&A With Ajinomoto Biopharma Services: Oligonucleotide Therapeutics - Partnering with the Right CDMO

Thank you for reading CMC Oligonucleotides and Peptides